1 / 5

TORPEDO TRIAL

TORPEDO TRIAL. T hrombus O bliteration by R apid P ercutaneous E ndovenous Intervention in D eep Venous O cclusion “TORPEDO” trial : Mid –Term results Mohsen Sharifi,MD,FACC, Mahshid Mehdipour, Curt Bay, PhD, Gary Smith,MD, Jalaladdin Sharifi,MD

asa
Download Presentation

TORPEDO TRIAL

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. TORPEDO TRIAL Thrombus Obliteration by Rapid Percutaneous Endovenous Intervention in Deep Venous Occlusion “TORPEDO” trial : Mid –Term results Mohsen Sharifi,MD,FACC, Mahshid Mehdipour, Curt Bay, PhD, Gary Smith,MD, Jalaladdin Sharifi,MD Arizona Cardiovascular Consultants & A.T. Still University, Mesa, AZ

  2. TORPEDO TRIAL First Randomized trial Evaluating Reduction of DVT Sequelae with Percutaneous Endovenous Intervention (PEVI)

  3. 183 Randomized Control No=92 PEVI No=91 8 pts Control 81 PEVI 88 F/U at 30±5months

  4. TORPEDO TRIAL Primary endpoints Post- thrombotic Syndrome Recurrent Venous Thromboembolic Disease Secondary Endpoints • Skin Induration • Leg Edema • Hospital Stay • Subjective Perception of Improvement • Bleeding

  5. ConclusionsPEVI + anticoagulation is superior to anticoagulation alone in: • Reduction of recurrent VTE. • Reduction of PTS • Reduction of hospital stay • Reduction of leg edema • Reduction of skin induration • Reduction in duration of parenteral anticoagulants • Subjective perception of improvement

More Related